STRS Ohio’s Revance Therapeutics, Inc. RVNC Stock Holding History

STRS Ohio’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100	Closed	-$304	–	2052
2024 Q4	$304	Hold	100	–	–	﹤0.01%	1878
2024 Q3	$519	Hold	100	–	–	﹤0.01%	1959
2024 Q2	$257	Hold	100	–	–	﹤0.01%	1948
2024 Q1	$0	Hold	100	–	–	﹤0.01%	2047
2023 Q4	$0	Hold	100	–	–	﹤0.01%	2033
2023 Q3	$1K	Hold	100	–	–	﹤0.01%	1928
2023 Q2	$2K	Sell	100 -500	-83%	-$15.6K	﹤0.01%	1924
2023 Q1	$19K	Buy	+600	New	+$18.7K	﹤0.01%	1873
2020 Q4	–	Sell	-1,300	Closed	-$32K	–	2302
2020 Q3	$32K	Buy	+1,300	New	+$34.1K	﹤0.01%	2034

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

STRS Ohio's RVNC Position: Q1 2025 in Review

STRS Ohio sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 100 shares — an estimated $304 sold.

STRS Ohio first reported a position in RVNC in Q3 2020 and held it in 9 quarters. The position peaked at $32K in Q3 2020. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

STRS Ohio reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
STRS Ohio sold 100 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $304.
STRS Ohio first reported a position in Revance Therapeutics, Inc. in Q3 2020 and held it in 9 quarters.
STRS Ohio's Revance Therapeutics, Inc. position peaked at $32K in Q3 2020.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on STRS Ohio's 13F filing for Q1 2025, filed 28 May 2025.